Covid-19 has made 2020 into a year like no other with 'stay
at home' orders and working from home the new normal.
Nonetheless, the tech and pharma industries continued to attract
immense antitrust scrutiny, with daily reports in the media and
pressure from politicians to address what some perceive to be
anticompetitive mergers by digital platforms and pharmaceutical
companies, even while innovation in both sectors continues at
breakneck speed. In this article, we discuss some of the most
noteworthy trends and developments in the high-tech and pharma
sectors over the past year, with an eye towards the unique issues
that are driving antitrust enforcement in the technology area.
Read more
